Basal cell carcinoma of skin
ICD-10 C44.9 ICD-11 2C32

Treatment of Basal Cell Carcinoma of Skin in Metastatic Disease (mBCC)

Clinical Scenario

This protocol addresses basal cell carcinoma of the skin that has reached the metastatic stage. Advanced BCC encompasses both locally advanced and metastatic presentations, with metastatic BCC (mBCC) requiring specific clinical management.

Patient Population

Patients with metastatic basal cell carcinoma (mBCC) — a subset of advanced BCC in which disease has spread beyond the primary skin site — particularly those for whom surgery or radiotherapy is not feasible or is contraindicated.

Treatment Approach (Partial Overview)

An electrochemotherapy-based approach may be considered in this setting as a treatment option. The complete drug selection, protocol specifics, and clinical decision steps are available in the full regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.ejca.2023.113254

Advanced BCC includes locally advanced BCC (laBCC) and metastatic BCC (mBCC).

ECT is a treatment option that may be offered when surgery or radiotherapy are not feasible or contraindicated.

ECT provides its antitumor effect through the permeabilisation of cancer cells to chemotherapeutic agents (bleomycin or cisplatin) by means of short, high-voltage, electric pulses which destabilise the cell membrane barrier allowing their intracellular access.

View source ↗